These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24395025)

  • 1. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.
    Stockwell MS; Broder K; LaRussa P; Lewis P; Fernandez N; Sharma D; Barrett A; Sosa J; Vellozzi C
    JAMA Pediatr; 2014 Mar; 168(3):211-9. PubMed ID: 24395025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination.
    Stockwell MS; Broder KR; Lewis P; Jakob K; Iqbal S; Fernandez N; Sharma D; Barrett A; LaRussa P
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e7-e14. PubMed ID: 27302328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine.
    Kawai AT; Martin D; Kulldorff M; Li L; Cole DV; McMahill-Walraven CN; Selvam N; Selvan MS; Lee GM
    Pediatrics; 2015 Oct; 136(4):e848-55. PubMed ID: 26371192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging.
    Stockwell MS; Marchant CD; Wodi AP; Barnett ED; Broder KR; Jakob K; Lewis P; Kattan M; Rezendes AM; Barrett A; Sharma D; Fernandez N; LaRussa P
    Vaccine; 2017 Dec; 35(50):6941-6948. PubMed ID: 29089191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years.
    Schwarz TF; Schmoele-Thoma B
    Vaccine; 2013 Jan; 31(2):291-4. PubMed ID: 23123107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.
    Frenck RW; Gurtman A; Rubino J; Smith W; van Cleeff M; Jayawardene D; Giardina PC; Emini EA; Gruber WC; Scott DA; Schmöle-Thoma B
    Clin Vaccine Immunol; 2012 Aug; 19(8):1296-303. PubMed ID: 22739693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.
    Schwarz TF; Flamaing J; Rümke HC; Penzes J; Juergens C; Wenz A; Jayawardene D; Giardina P; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2011 Jul; 29(32):5195-202. PubMed ID: 21619909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations.
    Walter EB; Klein NP; Wodi AP; Rountree W; Todd CA; Wiesner A; Duffy J; Marquez PL; Broder KR
    Pediatrics; 2020 Mar; 145(3):. PubMed ID: 32029684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.
    Lambert SB; Chuk LM; Nissen MD; Nolan TM; McVernon J; Booy R; Heron L; Richmond PC; Walls T; Marshall HS; Reynolds GJ; Hartel GF; Hu W; Lai MH
    Influenza Other Respir Viruses; 2013 Sep; 7(5):676-85. PubMed ID: 23551933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.
    Baker MA; Baer B; Kulldorff M; Zichittella L; Reindel R; DeLuccia S; Lipowicz H; Freitas K; Jin R; Yih WK
    PLoS Med; 2019 Jul; 16(7):e1002844. PubMed ID: 31265459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
    Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
    Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
    Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
    Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
    Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
    Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines.
    Baker MA; Jankosky C; Yih WK; Gruber S; Li L; Cocoros NM; Lipowicz H; Coronel-Moreno C; DeLuccia S; Lin ND; McMahill-Walraven CN; Menschik D; Selvan MS; Selvam N; Chen Tilney R; Zichittella L; Lee GM; Kawai AT
    Vaccine; 2020 Feb; 38(9):2166-2171. PubMed ID: 32019703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.